Effect of montelukast in experimental model of Parkinson's disease
- PMID: 29885451
- DOI: 10.1016/j.neulet.2018.05.052
Effect of montelukast in experimental model of Parkinson's disease
Abstract
Despite the availability of many drugs offering symptomatic relief in Parkinson's disease, there are no drugs available offering neuroprotective effect. Hence, it was decided to evaluate the neuroprotective effect of montelukast, an anti-inflammatory drug, in rotenone induced model of Parkinson's disease in rats. Forty eight male wistar rats were randomly divided into three groups. Group 1: Vehicle control, Group 2: Montelukast 5 mg/kg, Group 3: Montelukast 10 mg/kg. All the groups received rotenone 2.5 mg/kg intraperitoneally for 10 days as a disease inducing agent. The study drug montelukast was administered to respective groups orally from day 11 to day 24. On day 25, 24 h after 14 days of study drug administration, the rats were subjected to open field test, rota rod test and catalepsy test. Brain samples of rats from each group were collected for Malondialdehyde(MDA), Glutathione(GSH) and TNFα analysis. In the open field test both the doses of montelukast showed significant increase in the locomotor activity and also decreased the immobility time compared to vehicle (p < 0.05). In rotarod test, montelukast 5 mg/kg and 10 mg/kg showed significant increase in the time to fall, compared to vehicle (p < 0.05). In catalepsy test, both doses of montelukast significantly decreased the retraction time compared to vehicle(p < 0.05). The brain MDA levels were decreased and GSH levels were found to be higher in the two montelukast groups compared to vehicle (p < 0.05). TNFα levels too were decreased significantly on montelukast administration. Montelukast showed potential neuroprotective effect by virtue of its anti-oxidant and anti-inflammatory actions.
Keywords: Leukotrienes; Montelukast; Neuroprotection; TNFα.
Copyright © 2018 Elsevier B.V. All rights reserved.
Similar articles
-
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.Int J Mol Sci. 2021 May 25;22(11):5606. doi: 10.3390/ijms22115606. Int J Mol Sci. 2021. PMID: 34070609 Free PMC article. Review.
-
Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.Prostaglandins Other Lipid Mediat. 2012 Dec;99(3-4):131-9. doi: 10.1016/j.prostaglandins.2012.09.002. Epub 2012 Sep 15. Prostaglandins Other Lipid Mediat. 2012. PMID: 22986158
-
Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects.Toxicol Appl Pharmacol. 2018 Nov 1;358:76-85. doi: 10.1016/j.taap.2018.09.012. Epub 2018 Sep 15. Toxicol Appl Pharmacol. 2018. PMID: 30222980
-
Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats.Int Braz J Urol. 2015 Mar-Apr;41(2):279-87. doi: 10.1590/S1677-5538.IBJU.2015.02.14. Int Braz J Urol. 2015. PMID: 26005969 Free PMC article.
-
The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.Eur J Clin Pharmacol. 2017 Jul;73(7):799-809. doi: 10.1007/s00228-017-2242-2. Epub 2017 Apr 4. Eur J Clin Pharmacol. 2017. PMID: 28374082 Review.
Cited by
-
Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents.J Parkinsons Dis. 2024;14(7):1283-1300. doi: 10.3233/JPD-240353. J Parkinsons Dis. 2024. PMID: 39331111 Free PMC article. Review.
-
Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease.Int J Mol Sci. 2021 May 25;22(11):5606. doi: 10.3390/ijms22115606. Int J Mol Sci. 2021. PMID: 34070609 Free PMC article. Review.
-
Anti-enzymatic and DNA docking studies of montelukast: A multifaceted molecular scaffold with in vitro investigations, molecular expression analysis and molecular dynamics simulations.Heliyon. 2024 Jan 12;10(2):e24470. doi: 10.1016/j.heliyon.2024.e24470. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38298631 Free PMC article.
-
Leukotriene Signaling as a Target in α-Synucleinopathies.Biomolecules. 2022 Feb 23;12(3):346. doi: 10.3390/biom12030346. Biomolecules. 2022. PMID: 35327537 Free PMC article. Review.
-
Inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism via modulation of oxidative injury, and downregulation of inflammatory markers in experimental rats.Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3425-3435. doi: 10.1007/s00210-023-02812-y. Epub 2023 Nov 14. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37962585
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources